The novel DHODH inhibitor BAY 240234 is currently under phase 1 clinical trial (NCT03404726) for myeloid malignancies, and preclinical data showed differentiative effects in several AML cell lines, including THP-1, and three subcutaneous AML xenografts in vivo [18]. Here, DHODH is linked to acute myeloid leukemia.